Our free stock report includes 1 warning sign investors should be aware of before investing in Duopharma Biotech Berhad. Read ...

Duopharma Biotech Bhd's latest contract win brings its approved products purchase list (APPL) contract to 99 products, with a ...

Duopharma Biotech is 44.11%-owned by Permodalan Nasional Bhd (PNB). The Employees Provident Fund (EPF) also holds an 8.58% indirect stake in the group. Duopharma closed its fiscal year 2023 ...

It is hard to get excited after looking at Duopharma Biotech Berhad's (KLSE:DPHARMA) recent performance, when its stock has declined 10% over the past three months. We, however decided to study ...

PETALING JAYA: Duopharma Biotech Bhd ’s future earnings will still be underpinned by robust drug product purchase list or APPL for the government as well as potential synergies generated by ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

If you want to know who really controls Duopharma Biotech Berhad (KLSE:DPHARMA), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

It is hard to get excited after looking at Duopharma Biotech Berhad's (KLSE:DPHARMA) recent performance, when its stock has declined 10% over the past three months. We, however decided to study the ...

Trailing total returns as of 24/03/2025, which may include dividends or other distributions. Benchmark is FTSE Bursa Malaysia KLCI (^KLSE) Return 7148.KL FTSE Bursa Malaysia KLCI (^KLSE) ...